the dose record
BPC-157 dosage as the literature actually expresses it
Per-kilogram animal figures, the routes studied, the half-life, and the small human pilot doses — described as research data, never as a protocol for a person.
BPC-157 Dosage: How BPC-157 Doses Are Expressed in the Literature
BPC-157 dosage, as the research expresses it, is the whole point of this page, and the key fact is that doses are stated per kilogram of body weight, in animals. Rodent studies commonly use figures around 10 µg/kg and 10 ng/kg — and some tendon work went as low as 10 pg per rat — given most often by intraperitoneal injection [1]. These are animal-model figures. They are not human doses, they do not convert to a human dose by arithmetic, and this site does not perform that conversion.
The gastric-ulcer cytoprotection studies are more specific: BPC 157 was studied at 400 ng/kg and 800 ng/kg in rats, with the ulcer-formation-inhibition ratio of 45.7-65.6% reached at the higher doses [4]. Across the rodent literature the pattern is repeated daily dosing over a healing course, not a single administration — which is consistent with the peptide's rapid clearance rather than any claim about an ideal human schedule. Read against the BPC-157 references, every dose figure here is animal data.
Half-life and what it implies for the dose record
The first formal pharmacokinetic study reported a BPC-157 elimination half-life of under 30 minutes in rats and dogs, with linear pharmacokinetics and rapid breakdown into small peptide fragments [2]. Intramuscular bioavailability was about 14-19% in rats and 45-51% in dogs. A short half-life is why the animal protocols dose frequently: the parent peptide clears quickly, so repeated administration maintains exposure across a healing window.
It is worth stating what this half-life is not. It is not a human pharmacokinetic parameter — human PK for BPC-157 has not been characterized [2][8] — and it is not a dosing instruction. It is an animal clearance figure that helps explain the shape of the animal dose record.
Routes studied, and the small human pilot doses
BPC-157 has been studied across a wide range of routes: intraperitoneal (most common in rodent work), intramuscular, intragastric/peroral, local/intra-lesional, and — in the three human pilots only — intravenous, intravesical, and intra-articular [1][2][4][5][6][7]. The "stable gastric pentadecapeptide" descriptor reflects reported stability in gastric juice, which is why oral routes are studied at all; despite that, formal human oral pharmacokinetics are not established [2].
The human pilot doses are reported plainly and are the entire human dose record: a 2-person IV safety pilot used 10 mg then 20 mg by one-hour infusion [5], and a 12-patient interstitial-cystitis pilot used a single 10 mg intravesical instillation [6]. These are study doses administered under research conditions to characterize safety or feasibility — not validated treatment doses, and not guidance for any person.
Why the animal figures do not become a human dose
A recurring error in online dose discussion is to take a rodent per-kilogram figure and scale it to a human by body weight. The literature does not support that move. Allometric scaling between species is not linear by mass, the animal studies optimized for healing endpoints rather than for a human therapeutic window, and the routes that dominate the rodent record — intraperitoneal and intramuscular injection — are not the routes most people associate with the compound [1][2][4]. A 10 µg/kg rat figure is a statement about rats, not a hidden human prescription.
The pharmacokinetic gap makes the point sharper. Human PK for BPC-157 has not been characterized at all [2][8], which means the two quantities you would need to derive a human dose responsibly — clearance and bioavailability in humans — do not exist in the literature. This is why the entire dose record on this page is presented as research context and why the BPC-157 legal status of the compound, not a dosing table, is the more useful thing to understand for anyone weighing it.
Stability and reconstitution, as research handling
The peptide is supplied for research as a lyophilized (freeze-dried) powder and reconstituted in a diluent such as bacteriostatic water — a laboratory handling practice, described here as research context rather than as a protocol for use [2]. Its reported stability in gastric juice is the property that earned the "stable gastric pentadecapeptide" name and that keeps the oral route under study [2][4].
None of these handling details should be read as validated clinical procedure. Storage, reconstitution, and route in the research literature describe how investigators prepared the compound for experiments, not how a person should use it — and because product sold through non-regulated channels is not identity- or purity-verified outside formal studies [8], even the assumption that a given vial contains what its label claims is not something this site can underwrite.
How long should I stay on BPC-157?
No validated human duration exists. Published doses are per-kilogram animal-model figures studied over healing courses, not human protocols, and there is no clinical guidance on length of use [1][4][8]. The literature simply does not contain a human duration to cite, and this site will not invent one.
How long can you take BPC-157?
No validated human duration exists. All formal dosing in the record is expressed per kilogram in animals over defined study periods, and there is no clinical recommendation for length of human use [1][8]. Any specific human duration circulating online is an extrapolation, not a finding.